ESPE2021 ePoster Category 2 Adrenals and HPA Axis (57 abstracts)
1Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 2Department for BioMedical Research, University of Bern, Bern, Switzerland; 3Department of Pediatrics, Division of Endocrinology, Erasmus MC-Sophia, University Medical Center, Rotterdam, Netherlands; 4Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 5Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, National and Kapodistrian University of Athens Medical School, Athens, Greece; 6Division of Endocrinology and Metabolism, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
Introduction: Steroid profiling in children with congenital adrenal hyperplasia (CAH) is used to monitor the balance between androgen and cortisol metabolites and to decide on the optimal glucocorticoid dosage. Twenty-four hour collection is the gold standard for measurement of steroid metabolites in urine, because steroid production follows a circadian rhythm and is influenced by short-term stress and steroid drugs. For some children, e.g. those who were diapers, it is not feasible to collect urine over 24h non-invasively, and urine spot steroid assessments might still be an alternative in CAH.
Objective: To investigate whether steroid metabolites in 24h urine collections correlate with those determined in urine spot samples in children with CAH.
Methods: We collected 24h urine and urine spots from children and adolescents with CAH due to 21-hydroxylase deficiency and analysed 40 steroid metabolites using GC-MS (see Table). To assess the strength of correlations between 24h and spot urine metabolites, we calculated Kendalls tau-beta separate for morning and non-morning urine. We set the level to α=0.005 to account for multiple testing.
Results: Thirty patients provided both 24h collections and spot urine samples (n = 20 morning, n = 10 non-morning). Out of the 40 metabolites, there was a strong correlation between 24h and morning spot urine for 17 metabolites, and between 24h and non-morning spot urine for 9 metabolites (tau>0.45, P < 0.005). Specifically, correlations were noted for progesterones, corticosterones, tetrahydroaldosterone, androgens, estriol, tetrahydro-11-deoxycortisol, but not for the cortisol metabolites (Table).
| 24h vs morning n = 20 | 24h vs non-morning n = 10 | ||
| Progesterones | |||
| 17-hydroxypregnanolone | + | + | |
| Pregnanediol | + | ||
| Pregnanetriol | + | + | |
| 11-oxo-pregnanetriol | + | + | |
| Corticosterones | |||
| TH-deoxycorticosterone | + | ||
| TH-11-DH-corticosterone | |||
| TH-corticosterone | + | ||
| 5α-TH-corticosterone | + | + | |
| TH-Aldosterone | + | ||
| Androgens | |||
| Androsterone | + | + | |
| Etiocholanolone | + | + | |
| Dihydroandrosterone | + | + | |
| 11-oxo-etiocholanolone | |||
| 11β-OH-androsterone | + | + | |
| 11β-OH-etiocholanolone | + | ||
| Dehydroepiandrosterone | + | ||
| Androstenediol | |||
| 16α-OH-DHEA | |||
| Androstenetriol | |||
| Pregnenetriol | + | ||
| Testosterone | |||
| 5α-dihydrotestosterone | |||
| Estrogens | |||
| Estriol | + | ||
| 17β-estradiol | |||
| TH-11-deoxycortisol | + | + | |
| Cortisols | |||
| Cortisone | |||
| TH-cortisone | |||
| β-cortolone | |||
| 20α-dihydrocortisone | |||
| 20β-dihydrocortisone | |||
| Cortisol | |||
| TH-cortisol | |||
| 5α-TH-cortisol | |||
| α-cortole | |||
| β-cortole | |||
| 20α-dihydrocortisol | |||
| 20β-dihydrocortisol | |||
| 6β-OH-cortisol | |||
| 18-OH-cortisol | |||
| α-cortolone | |||
| Legend: +, strong correlation (Kendalls tau >0.45 and P < 0.005); empty cells, correlation not significant. | |||
Conclusions: Urinary steroid profiling in children with CAH revealed correlations between 24h urine specimens and spot urines. Spot urine might suffice to recognize the specific pattern of 21-hydroxylase deficiency for diagnostics (e.g. through marker metabolites 11-oxo-pregnanetriol, TH-11-deoxycortisol). Whether a spot urine can inform about metabolic control of treatment in CAH needs to be further tested in a larger number of specimens.